Adinazolam, a Benzodiazepine-Type New Psychoactive Substance, Has Abuse Potential and Induces Withdrawal Symptoms in Rodents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Su-Bin | - |
dc.contributor.author | Lee, Jae-Gyeong | - |
dc.contributor.author | Lee, Youyoung | - |
dc.contributor.author | Kook, Wun-A | - |
dc.contributor.author | Kim, Seon-Kyung | - |
dc.contributor.author | Donio, Audrey Lynn | - |
dc.contributor.author | Min, Hee-Won | - |
dc.contributor.author | Kim, Young-Jung | - |
dc.contributor.author | Lee, Seok-Yong | - |
dc.contributor.author | Jang, Choon-Gon | - |
dc.date.accessioned | 2023-10-16T03:46:41Z | - |
dc.date.available | 2023-10-16T03:46:41Z | - |
dc.date.issued | 2023-09-11 | - |
dc.identifier.issn | 1948-7193 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/108631 | - |
dc.description.abstract | Adinazolam (ADZ) is a benzodiazepine-type new psychoactive substance (NPS) with anxiolytic, anticonvulsant, and antidepressant effects. High ADZ doses have been reported to impair psychomotor performance and memory; however, the abuse potential and drug dependence of ADZ have not yet been fully investigated. In this study, we evaluated whether ADZ has abuse potential and leads to drug dependence and withdrawal symptoms. The intravenous self-administration (IVSA) test revealed that ADZ (0.01, 0.03, and 0.1 mg/kg/infusion) was self-administered significantly above vehicle levels, suggesting the reinforcing effect of ADZ. Furthermore, we revealed that treatment discontinuation following chronic ADZ administration (3 and 6 mg/kg) caused several somatic withdrawal symptoms in mice, including body tremor. Moreover, it induced motivational withdrawal signs, such as anxiety-related behavior in the elevated plus maze (EPM) test and memory deficits in the Y-maze test. After the IVSA test, an enzyme-linked immunosorbent assay (ELISA) showed that ADZ administration significantly increased the dopamine contents in the thalamus, nucleus accumbens (NAc), and ventral tegmental area (VTA). This finding was also supported by the results of the Western blot. Taken together, our results suggest that ADZ has abuse potential and can lead to drug dependence and withdrawal syndrome. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Adinazolam, a Benzodiazepine-Type New Psychoactive Substance, Has Abuse Potential and Induces Withdrawal Symptoms in Rodents | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1021/acschemneuro.3c00346 | - |
dc.identifier.scopusid | 2-s2.0-85171900693 | - |
dc.identifier.wosid | 001065973500001 | - |
dc.identifier.bibliographicCitation | ACS CHEMICAL NEUROSCIENCE, v.14, no.18, pp 3487 - 3498 | - |
dc.citation.title | ACS CHEMICAL NEUROSCIENCE | - |
dc.citation.volume | 14 | - |
dc.citation.number | 18 | - |
dc.citation.startPage | 3487 | - |
dc.citation.endPage | 3498 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | ELEVATED PLUS-MAZE | - |
dc.subject.keywordPlus | DOPAMINE TRANSPORTER | - |
dc.subject.keywordPlus | NUCLEUS-ACCUMBENS | - |
dc.subject.keywordPlus | COCAINE-SEEKING | - |
dc.subject.keywordPlus | DEPENDENCE | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordPlus | BEHAVIOR | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordAuthor | Adinazolam | - |
dc.subject.keywordAuthor | Benzodiazepine | - |
dc.subject.keywordAuthor | Addiction | - |
dc.subject.keywordAuthor | Self-administration | - |
dc.subject.keywordAuthor | Withdrawal | - |
dc.subject.keywordAuthor | Dopaminergic pathway | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.